Mario Strazzabosco MD, PhD

Similar documents
Bile Acids and Liver Fibrosis Causative Agent and Therapeutic Tool

Intestinal Microbiota in Health and Disease

The intrahepatic bile ducts comprise a complex 3-dimensional

Biliary tract diseases of the liver

PROGRESS: Beginning to Understand the Genetic Predisposition to PSC

Prognosis of untreated Primary Sclerosing Cholangitis (PSC) Erik Christensen Copenhagen, Denmark

Anatomy of the biliary tract

Current Concepts in the Management and Treatment of PBC & PSC

Overview of PSC Making the Diagnosis

Interface hepatitis in PBC: Prognostic marker and therapeutic target

Biliary Atresia. Karen F. Murray, MD Professor of Pediatrics Director, Hepatobiliary Program Seattle Children s

Overview of PSC Jayant A. Talwalkar, MD, MPH Associate Professor of Medicine Mayo Clinic Rochester, MN

Approach to the cholestatic patient

Commensal Bacteria, Toll-like Receptors and Intestinal Injury. Journal Club December 16, 2004

Chronic Biliary Disease. Dr Susan Davies & Dr Bill Griffiths

Noncalculous Biliary Disease Dean Abramson, M.D. Gastroenterologists, P.C. Cedar Rapids. Cholestasis

Primary Sclerosing Cholangitis. Bibleclass Felix Brunner

Liver Disease in Cystic Fibrosis

CASE 1 Plasma Cell Infiltrates: Significance in post liver transplantation and in chronic liver disease

DOWNLOAD OR READ : PRIMARY SCLEROSING CHOLANGITIS PDF EBOOK EPUB MOBI

ACCME/Disclosures. PBC and PSC Revisited 4/6/2016. Primary Biliary Cirrhosis Cholangitis (PBC)

Understanding Root Cause: Pathogenesis of Hepatic Fibrosis

Unique Aspects of the Neonatal Immune System Provide Clues to the Pathogenesis of Biliary Atresia. Disclosures. Objectives

Hépatopathies auto-immunes

Immune response to infection

2 Cholangiocyte Biology

Necrotizing Enterocolitis: The Role of the Immune System

Navigating the Biliary Tract with CT & MR: An Imaging Approach to Bile Duct Obstruction

HOW TO DEAL WITH THOSE ABNORMAL LIVER ENZYMES David C. Twedt DVM, DACVIM Colorado State University Fort Collins, CO

Primary sclerosing cholangitis (PSC) is a rare but important

Chronic Cholestatic Liver Diseases

Autoimmune hepatitis

Pediatric PSC A children s tale

Tolerance, autoimmunity and the pathogenesis of immunemediated inflammatory diseases. Abul K. Abbas UCSF

Innate Immunity. Connection Between Innate and Adaptive Immunity. Know Differences and Provide Examples Chapter 3. Antimicrobial peptide psoriasin

Extrahepatic Biliary Obstruction. Ductal Diseases: Stones Tumors. Acute Injury: Viral Hepatitis Toxin (APAP/Etoh) Reye s Shock.

Improving the Lives of Patients with Liver Diseases

Primary Sclerosing Cholangitis and Cholestatic liver diseases. Ahsan M Bhatti MD, FACP Bhatti Gastroenterology Consultants

ALLERGY AND AUTOIMMUNITY

LIVER SPECIALTY CONFERENCE USCAP Maha Guindi, M.D. Clinical Professor of Pathology Cedars-Sinai Medical Center Los Angeles, CA

ACCME/Disclosures. The Overlap Syndromes: Do They Exist? Key Points and Questions 4/6/2016. Hans Popper Hepatopathology Society

Innate Immunity. Chapter 3. Connection Between Innate and Adaptive Immunity. Know Differences and Provide Examples. Antimicrobial peptide psoriasin

Slide 7 demonstrates acute pericholangitisis with neutrophils around proliferating bile ducts.

Aberrant Expression of Keratin 7 in Hepatocytes as a Predictive Marker of Rapid Progression to Hepatic Failure in Asymptomatic Primary Biliary

Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need?

Scott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION

Portal Fibroblasts in Biliary Fibrosis

Innate immune regulation of T-helper (Th) cell homeostasis in the intestine

ACG Clinical Guideline: Primary Sclerosing Cholangitis

Autoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP

The Duct. $514,706 for Research Grants Awarded Since The Giant Steps of a Small Organization

REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY AND HEPATOLOGY. Pathogenesis of Cholestatic Liver Disease and Therapeutic Approaches

Tratamiento endoscópico de la CEP. En quien como y cuando?

Colangitis Esclerosante Primaria: Manejo Clínico y Endoscópico

Autoimmune Liver Diseases

AESOP Overview and Inclusion/Exclusion Criteria Richard Pencek, PhD

Alcoholic hepatitis is a drug-induced disorder

Innate immunity. Abul K. Abbas University of California San Francisco. FOCiS

Management of cholestatic diseases Today and tomorrow

Transplant Hepatology

The role of Lipoxin A4 in Cystic Fibrosis Lung Disease

Current Management of Biliary Atresia. Janeen Jordan, MD PGY5 Surgery Grand Rounds November 19, 2007

Pictorial review of Benign Biliary tract abnormality on MRCP/MRI Liver with Endoscopic (including splyglass) and Endoscopic Ultrasound correlation

Nottingham Patterns of liver fibrosis and their clinical significance

Activation of PPAR-γ Signaling as a Novel Target to Limit NFκB-Dependent Inflammation in Cystic Fibrosis Biliary Epithelium

Liver National EQA Scheme. Circulation Q Birmingham, March 15 th 2005

17 th International Conference of the Inflammation Research Association: Wednesday AM (Day 4) September 9-13, 2012

Innate immunity as a therapeutic target in IBD. Elke Cario Division of Gastroenterology & Hepatology University Hospital of Essen Essen, Germany

INFLAMMATORY BOWEL DISEASE. Jean-Paul Achkar, MD Center for Inflammatory Bowel Disease Cleveland Clinic

Key Points: Autoimmune Liver Disease: Update for Pathologists from the Hepatologist s Perspective. Jenny Heathcote, MD. University of Toronto

21/07/2017. Update on Autoimmune Biliary Disease. Changing Role of Liver Biopsy in PBC and PSC. Primary Biliary Cirrhosis Cholangitis

Congenital Disorders of the Canine and Feline Biliary Tree

A Review of Liver Function Tests. James Gray Gastroenterology Vancouver

Genetics. Environment. You Are Only 10% Human. Pathogenesis of IBD. Advances in the Pathogenesis of IBD: Genetics Leads to Function IBD

Virchow s Hypothesis lymphorecticular infiltration of cancer reflected the origin of cancer at sites of inflammation

Hepatocytes produce. Proteins Clotting factors Hormones. Bile Flow

USCAP PEDIATRIC PATHOLOGY Slide Session

Study Design to Validate Biomarkers of Therapeutic Response in NASH Due to Cirrhosis

Case Report Successful Treatment of Recurrent Primary Sclerosing Cholangitis after Orthotopic Liver Transplantation with Oral Vancomycin

Differential responses of human colonic ILCs to gut commensal bacteria altered during HIV infection

Diagnosis and Management of Primary Sclerosing Cholangitis:

Nutrition & Gut Immunity

Chronic Cholestatic Liver Disease

Risk stratification in PBC

Restrictive lung diseases

Le Funzioni dei Colangiociti e delle Cellule Endoteliali.

NEURO- GASTRO- ENTEROLOGY & MOTILITY OESO- PHAGUS LOGY. Room A Room B Room C Room E1 Room E2 Room M Room N1 Room N2 Room L8 Room 1.

Dysbiosis & Inflammation

Hangzhou, 15 March Ulrich Beuers Department of Gastroenterology and Hepatology Academic Medical Center University of Amsterdam

Understanding clinical aspects of Crohn s disease and ulcerative colitis: Implications for the basic scientist

News dalla ricerca: identificazione di nuove molecole come target di terapia nelle infiammazioni intestinali

The Norwegian PSC Research Center Biobank

DNA vaccine, peripheral T-cell tolerance modulation 185

Primary Sclerosing Cholangitis Medical Management

Liver disease in cystic fibrosis

Biliary tract tumors

Review Article Contribution of Gut Bacteria to Liver Pathobiology

Liver Pathology Symposium - medical livers

The Role of Innate Immunity in Alcoholic Liver Disease

PBC/AIH variant/ overlap syndrome vs PBC with hepatitic features?

Transcription:

Mario Strazzabosco MD, PhD Professor of Medicine & Gastroenterology Deputy Director, Yale Liver Center, Director, Hepatobiliary Cancer Program Yale University School of Medicine Director Master Program in Transplant Medicine Scientific Director CeLiveR Network University of Milan-Bicocca

Defining features of PSC Bile duct damage with portal inflamma;on and peribiliary sclerosis Segmental bile ducts sclerosis and beading Associa;on with IBD PSC INFLAMMATORY BOWEL DISEASE

PSC histology

Progressive biliary damage in PSC PSC stage III PSC stage II PSC stage IV

Biology of cholangiocytes Bile hydration and alkalinization Reactivity Stem cell potential

Ductules or Cholangioles Hepatocytes Small Bile Duct Canal of Hering Small Cholangiocytes Lumen Large Cholangiocytes Secretin CFTR PKA ATP SR Duodenum Large Bile Duct camp Na - ATP HCO3- H 2O TGR5 Cl- ClK+ N a+ + H 2O Cl ClCa Ca2+ ClHCO3- Na + P2Y2 H+

Cholangiopathies result from the epithelial reac;on to liver damage and its repair/regenera;on acempts Inflammation Fibrosis Cholestasis Cholangiocyte Death (Lytic or Apoptotic) Reactive Proliferation of cholangiocytes Neoplastic transformation

Auto / Allo Immunity (i.e., PBC, OLT rejection) Xenobiotics (i.e., 5-fluouracil) Exotoxins / Infection (i.e., bacterial antigens) Endotoxins (i.e., bile acids) Initial Insult to Biliary Epithelial Cells Genetic Defects (i.e.,cf, MDR3 defect) Inflammatory Response resolution Chronic Inflammation persistence/progression Cholestasis Ductopenia BileDuct Proliferation Fibrosis Malignant Transformation Lazaridis, Strazzabosco and LaRusso, Gastroenterology 2004

Gene;c Cholangiopathies are the RoseCa Stone CF cholangiopathy Alagille ADPKD Inversin and biliary atresia Claudin and PSC Gene;c Cholangiop athies CHF Caroli Disease MDR3 deficency

Cystic Fibrosis- causes a progressive sclerosing cholangiopathy in a subset of patients H 2 O Cl - Chronic cholestasis predisposes the biliary epithelium to damages

Fibrosing cholangiopathies in Systemic conditions PSC INFLAMMATORY BOWEL DISEASE Liver Disease Cystic Fibrosis A two hit phenomenon?

Altered Innate Immunity Response of the Biliary Epithelium to portal endotoxins cause bilairy disease in Cys;c Fibrosis CFTR KO mice possess the bile secretory defect of Cys;c Fibrosis, but do not develop liver disease Experimental coli;s generates liver disease in CFTR KO mice, but not in their normal licermate Liver disease caused by coli;s in CFTR KO animals does not improve when bile secre;on is restore using therapeu;c bile acids Cholangiocytes isolated from CFTR KO mice present an exaggerated inflammatory response to endoxin Toll like receptor 4 pathway is ac;vated with loss of the normal endotoxin tolerance R. Fiorotto, M. Strazzabosco, EASL meeting 2010

Biliary epithelium protects against pathogens by expressing Toll like receptors (TLRs) (Szabo G. et al., Hepatology 2006) TLRs belong to a family of protein that recognize and discriminate between specific paaerns of microbial components (i.e. LPS, DNA, RNA, flagellin) In normal condikons a process of endotoxin tolerance prevents excessive inflammakon IN CysKc Fibrosis, CFTR deficiency causes a loss of endotoxin tolerance and in the presence of a second hit, such as coliks, the dysregulated inflammatory response causes liver disease

Hypothesis: a second hit may in part explain of PSC pathogenesis Leaky gut mucosa Bacterial constituents are delivered into the portal circulation Cholangiocyte T-cell An inflammatory response is triggered in conditions where endotoxin tolerance is decreased because of a cholangiocyte dysfunction (such as CFTR deficiency, or TGR5 or Gllypican 6, etc)

Cellular Cross-talk in Cholangiopathies Reactive Cholangiocytes PMN IL-8 Kupffer cell MCP-1 IL-1, IL-6 TNFa NO IFN γ IL-8 HGF ET-1 PDGF-BB TGF-β2 NO CTGF HGF ET-1 IL-6 T-cell Quiescent stellate cell Portal fibroblast Activated stellate cell or myofibroblast Reparative events of liver damage Liver Fibrosis

Cholangiocyte inos and Nitrotyrosine are increased in Primary Sclerosing Cholangitis inos 3-Nitrotyrosine Secretin AC camp Cl- RNOS Endotoxins Cytokines NO. inos ClHCO 3

PSC Partners Seeking a Care For all those whose care is our concern, the work goes on, the cause endures, the hope is real, and the dream shall come true Modified from Edward Kennedy, 1980